首页> 外文期刊>The Lancet >Milestones in treatment: the tipping point and the ResQ Trial.
【24h】

Milestones in treatment: the tipping point and the ResQ Trial.

机译:治疗里程碑:提示点和补议试验。

获取原文
获取原文并翻译 | 示例
       

摘要

In his Comment on the ResQ Trial, Peter Nagele suggests that enrolment of a larger cohort could have changed the findings of the ResQ Trial. However, figure 5 of the study shows results with an evident temporal consistency of the beneficial effect, making it extremely unlikely that the results would change. Nagele recommends not to change cardiopulmonary resuscitation (CPR) practice on the basis of the results of the ResQ Trial and on the positive results of the previous four studies on active compression-decompression CPR with an impedance threshold device, including three by our group, claiming that there is not enough evidence. To support his statement, Nagele indicates that two components of the new CPR method when applied independently have not shown definitive benefit. He misses the point of the substantial physiological synergy with the combination of the two devices that led to the current study. Actually, the new clinical trial results were consistent with the results from all the European studies.
机译:在他对RESQ审判的评论中,Peter Nagele表示,较大的队列的入学可能会改变了补议审判的结果。然而,该研究的图5显示出结果具有明显的时间一致性的有益效果,使得结果极不可能改变。 Nagele建议不要根据Resq试验的结果改变心肺复苏(CPR)实践,并在前四项研究的积极压缩减压CPR与阻抗阈值装置的阳性结果,包括我们的小组,声称没有足够的证据。为了支持他的陈述,Nagele表明,当申请独立申请时,新的CPR方法的两种组成部分没有显示明确的益处。他错过了具有导致目前研究的两种器件的组合的实质性生理协同作用。实际上,新的临床试验结果与来自所有欧洲研究的结果一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号